Advertisement

Differentiated Thyroid Cancer with Brain Metastasis

  • Gülin Uçmak
  • Burcu Esen Akkaş
Chapter

Abstract

Differentiated thyroid cancer is associated with favorable prognosis. The presence of distant metastases is generally rare. The most common sites of distant metastases are the lungs and bones followed by the brain and liver. Even with distant metastases, the 10-year survival can reach up to 50% in a majority of patients. However, the prognosis of patients with brain metastases generally differs and associates with cancer-associated mortality. In this chapter, the clinical progression and the diagnosis of brain metastases on follow-up are presented in a patient with papillary thyroid carcinoma.

Keywords

Brain metastases Thyroid cancer Progression Thyroglobulin 

References

  1. 1.
    Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL. Variables predicting distant metastases in thyroid cancer. Laryngoscope. 2005;115:661–7.CrossRefGoogle Scholar
  2. 2.
    Henriques de Figueiredo B, Godbert Y, Soubeyran I, Carrat X, Lagarde P, Cazeau A, et al. Brain metastases from thyroid carcinoma. A retrospective study of 21 patients. Thyroid. 2014;24:270–7.CrossRefGoogle Scholar
  3. 3.
    Slutzky-Shraga I, Gorshtein A, Popovitzer A, Robenshtok E, Tsvetov G, Akirov A, et al. Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases. Oncol Lett. 2018;15:672–6.  https://doi.org/10.3892/ol.2017.7325.CrossRefPubMedGoogle Scholar
  4. 4.
    Al-Dhahri SF, Al-Amro AS, Al-Shakwer W, Terkawi AS. Cerebellar mass as a primary presentation of papillary thyroid carcinoma: case report and literature review. Head Neck Oncol. 2009;1:23.  https://doi.org/10.1186/1758-3284-1-23.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;26:1–133.CrossRefGoogle Scholar
  6. 6.
    Tian LJ, Zhuang HQ, Yuan ZY. A comparison between CyberKnife and neurosurgery in solitary brain metastases from non-small cell lung cancer. Clin Neurol Neurosurg. 2013;115:2009–14.  https://doi.org/10.1016/j.clineuro.2013.06.006.CrossRefGoogle Scholar
  7. 7.
    McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer. 2003;98:356–62.CrossRefGoogle Scholar
  8. 8.
    Vrachimis A, Schmid KW, Jürgens H, Schober O, Weckesser M, Riemann B. Cerebral metastases from thyroid carcinoma: complete remission following radioiodine treatment. Dtsch Arztebl Int. 2013;110:861–6.  https://doi.org/10.3238/arztebl.2013.0861.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:3637–42.CrossRefGoogle Scholar
  10. 10.
    Miranda ER, Padrão EL, Silva BC, De Marco L, Sarquis MS. Papillary thyroid carcinoma with brain metastases: an unusual 10-year-survival case. Thyroid. 2010;20:657–61.  https://doi.org/10.1089/thy.2009.0442.CrossRefPubMedGoogle Scholar
  11. 11.
    Nieder C, Nestle U, Motaref B, Walter K, Niewald M, Schnabel K. Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys. 2000;46:297–302.CrossRefGoogle Scholar
  12. 12.
    Soffietti R, Trevisan E, Ruda R. Targeted therapy in brain metastasis. Curr Opin Oncol. 2012;24:679–86.CrossRefGoogle Scholar
  13. 13.
    Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol. 2014;16:276.  https://doi.org/10.1007/s11940-013-0276-z.CrossRefPubMedGoogle Scholar
  14. 14.
    Choi J, Kim JW, Keum YS, Lee IJ. The largest known survival analysis of patients with brain metastasis from thyroid Cancer based on prognostic groups. PLoS One. 2016;11:e0154739.  https://doi.org/10.1371/journal.pone.0154739.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Akkas BE, Demirel BB, Vural GU. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography. Thyroid. 2014;24:287–95.  https://doi.org/10.1089/thy.2013.019.CrossRefPubMedGoogle Scholar
  16. 16.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37:953–9.  https://doi.org/10.1097/RLU.0b013e31825b2057.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cacho-Diaza B, Cuevas-Ramos D, Spinola-Marono H, Reyes-Soto G, Olvera-Manzanilla E, Monroy-Sosa A, et al. Thyroid cancer brain metastases and thyroglobulin. J Endocrinol Metab. 2016;6:90–4.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Gülin Uçmak
    • 1
  • Burcu Esen Akkaş
    • 1
  1. 1.Department of Nuclear MedicineUniversity of Health Sciences (SBÜ) Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalAnkaraTurkey

Personalised recommendations